PCDHB3

Across TCGA pan-cancer cohorts, PCDHB3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCDHB3 data layer compared with 30 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PCDHB3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB3 expression acts as an unfavorable survival marker.

CESC, BLCA, and LIHC are the cancer types where PCDHB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.081	0.836	<.001	30	view →
BLCA	DFS	Median	All	0.094	0.594	.001	21	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
KIRP	DFS	Median	All	0.519	0.919	.019	6	view →
SKCM	OS	Median	III,IV	0.681	0.852	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCDHB3–CESC (OS)

Open the CESC breakdown →